South Korean Plan To Shorten IND Approvals Raises Competition With Singapore For Clinical Trials Hub
This article was originally published in PharmAsia News
Patient differences will come into sharper relief in attracting Phase I clinical trials if, as expected, South Korea cuts its IND approval timeline near par with Singapore.
You may also be interested in...
SEOUL - Korea FDA is gearing up to release guidelines on Phase 0 clinical trials in the first half of next year under its broader ambition to draw more early-stage clinical trials to the country
SINGAPORE - Pfizer expects to see drugs discovered and developed in Asia brought into the clinic in about three years, Pfizer's Pharma Therapeutics R&D Head Martin Mackay told local reporters April 7 during a press conference at the company's Clinical Research Unit at Raffles Hospital in Singapore
SEOUL - South Korea is drawing more Phase I and Phase II clinical trials from its former foothold in Phase III and post-approval trials, Korea National Enterprise for Clinical Trials reported